Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH....
Main Authors: | Jain, Mukul R., Giri, Suresh R., Bhoi, Bibhuti, Trivedi, Chitrang, Rath, Akshyaya, Rathod, Rohan, Ranvir, Ramchandra, Kadam, Shekhar, Patel, Hiren, Swain, Prabodha, Roy, Sib Sankar, Das, Nabanita, Karmakar, Eshani, Wahli, Walter, Patel, Pankaj R. |
---|---|
Other Authors: | Lee Kong Chian School of Medicine (LKCMedicine) |
Format: | Journal Article |
Language: | English |
Published: |
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/106322 http://hdl.handle.net/10220/49606 |
Similar Items
-
Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet
by: Suresh R. Giri, et al.
Published: (2023-01-01) -
Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
by: Sosale A, et al.
Published: (2015-04-01) -
Repurposing dimethyl fumarate for gastric ulcer and ulcerative colitis: Evidence of local efficacy without systemic side effect
by: Vishal Patel, et al.
Published: (2022-12-01) -
Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia
by: Arijit Ghosh, et al.
Published: (2016-03-01) -
Saroglitazar ameliorates monosodium glutamate-induced obesity and associated inflammation in Wistar rats: Plausible role of NLRP3 inflammasome and NF- κB
by: Sayima Nabi, et al.
Published: (2022-07-01)